Content about Smith, Kline & French

April 22, 2012

A lot has happened across GlaxoSmithKline’s consumer division in the past year. Drug Store News spoke with GSK Consumer chief marketing officer John Graham and chief customer officer Keith Loranger about the next move to be made out of the consumer division’s new playbook.

A lot has happened across GlaxoSmithKline’s consumer division in the past year. Drug Store News spoke with GSK Consumer chief marketing officer John Graham and chief customer officer Keith Loranger about the next move to be made out of the consumer division’s new playbook.

June 21, 2012

This may be the year of the legacy brands as two companies that recently acquired separate brand portfolios from GlaxoSmithKline focus on reinvigorating consumer attention to their respective product lines.


This may be the year of the legacy brands as two companies that recently acquired separate brand portfolios from GlaxoSmithKline focus on reinvigorating consumer attention to their respective product lines.


Prestige Brands will be adding 17 former GSK brands to its stable of legacy brands that already includes Luden’s and Dramamine. The company recently identified the five key GSK-acquired brands that Prestige will be focusing on in terms of both marketing support and new product development — BC, Goody’s, Debrox, Gaviscon and Beano.


May 15, 2012

GlaxoSmithKline is acquiring the remainder of a privately owned research and development company, GSK said Tuesday.

LONDON — GlaxoSmithKline is acquiring the remainder of a privately owned research and development company, GSK said Tuesday.

The British drug maker announced that it would buy the shares of Cellzome it doesn't already own for $99 million. Cellzome has labs in the United Kingdom and Germany, and will become part of GSK's research and development organization. The company, of which GSK currently owns 19.98%, develops technologies for profiling compounds in cells and patient samples.

April 3, 2012

Prestige Brands Holdings on Monday announced that it has completed the purchase of the two remaining brands of the 17 brands it agreed to acquire from GlaxoSmithKline; the purchase of Debrox ear wax remover and Gly-Oxide oral rinse completes the transaction.

IRVINGTON, N.Y. — Prestige Brands Holdings on Monday announced that it has completed the purchase of the two remaining brands of the 17 brands it agreed to acquire from GlaxoSmithKline; the purchase of Debrox ear wax remover and Gly-Oxide oral rinse completes the transaction.

For all 17 brands, Prestige paid a total of $660 million in cash plus a customary post-closing inventory adjustment under the original terms of the agreements.

February 2, 2012

Prestige Brands on Tuesday announced that it has completed its previously announced purchase of 15-of-the-17 brands it agreed to acquire from GlaxoSmithKline.

IRVINGTON, N.Y. — Prestige Brands on Tuesday announced that it has completed its previously announced purchase of 15-of-the-17 brands it agreed to acquire from GlaxoSmithKline.

Prestige did not identify the two brand acquisitions not yet completed.

The former GSK brands represent approximately $200 million in annual revenues, which is projected to push Prestige annual revenues above $600 million, Prestige stated in an investor presentation in December.

December 20, 2011

Prestige on Tuesday acquired 17 over-the-counter brands from GlaxoSmithKline for a total of $660 million in cash.

IRVINGTON, N.Y. — Prestige on Tuesday acquired 17 over-the-counter brands from GlaxoSmithKline for a total of $660 million in cash. Among the brands Prestige acquired are the pain relievers BC, Goody's and Ecotrin brands; digestive brands Beano, Gaviscon, Phazyme, Tagamet and Fiber Choice; and the Sominex sleep aid brand.

December 14, 2011

Diplomat Specialty Pharmacy has hired Craig Stephens as group VP business development and trade relations, the company said Wednesday.

FLINT, Mich. — Diplomat Specialty Pharmacy has hired Craig Stephens as group VP business development and trade relations, the company said Wednesday.

September 13, 2011

GlaxoSmithKline's Consumer Healthcare division has appointed a former Kraft Foods executive as its new chief customer officer.

PITTSBURGH — GlaxoSmithKline's Consumer Healthcare division has appointed a former Kraft Foods executive as its new chief customer officer.

In his new role, Keith Loranger will be responsible for leading the GSK Consumer Healthcare’s sales function to increase sales and profit for the company’s oral health and wellness categories, including such brands as Aquafresh, NicoDerm CQ and Tums, among others. Prior to joining the company, Loranger served as Kraft Foods' customer VP international strategy after joining the company in 1985.

September 1, 2011

GlaxoSmithKline on Thursday announced that 25-year veteran Clark Brown, VP sales at GSK Consumer Healthcare, will be leaving the organization effective Sept. 2.

PITTSBURGH — GlaxoSmithKline on Thursday announced that 25-year veteran Clark Brown, VP sales at GSK Consumer Healthcare, will be leaving the organization effective Sept. 2.

“Clark has been a valuable team member throughout his many years with GSK, and his passion and effective leadership of the U.S. consumer sales team has been critical to the success of our business,” stated Colin Mackenzie, president GSK Consumer Healthcare North America.

August 9, 2011

GlaxoSmithKline Consumer Healthcare on Monday named John Graham chief marketing officer for Consumer Healthcare, North America.

PITTSBURGH — GlaxoSmithKline Consumer Healthcare on Monday named John Graham chief marketing officer for Consumer Healthcare, North America.

July 28, 2011

GlaxoSmithKline expects to close the deal on the divestiture of several over-the-counter brands that were identified in April, the company stated Tuesday as part of its second-quarter earnings results.

PHILADELPHIA — GlaxoSmithKline expects to close the deal on the divestiture of several over-the-counter brands that were identified in April, the company stated Tuesday as part of its second-quarter earnings results.

"The divestment of noncore OTC assets in the [United States] and Europe will further aid our strategy to accelerate growth and increase the focus of our Consumer Healthcare business," GSK stated. "We are making progress to divest these products by late 2011, subject to realizing appropriate value for shareholders."

June 14, 2011

GlaxoSmithKline has garnered strong interest in its portfolio of legacy brands that were placed on the sales block earlier this year, according to a Reuters report published Tuesday. And that interest is likely to pick up in the coming months, GSK CEO Andrew Witty told reporters during a meeting of pharmaceutical industry executives.

BRUSSELS — GlaxoSmithKline has garnered strong interest in its portfolio of legacy brands that were placed on the sales block earlier this year, according to a Reuters report published Tuesday. And that interest is likely to pick up in the coming months, GSK CEO Andrew Witty told reporters during a meeting of pharmaceutical industry executives.

The interest is coming from both established consumer healthcare companies, as well as private equity houses, the report noted.

April 15, 2011

Duh, winning! Because there are no losers in this. GlaxoSmithKline will be able to funnel its extensive marketing dollars into a stable of poised-to-explode brands, niche marketers can take those brands being sold and breathe fresh marketing life into them and retailers now benefit most of all because a greater portfolio of brands are being marketed with gusto.

WHAT IT MEANS AND WHY IT’S IMPORTANT — Duh, winning! Because there are no losers in this. GlaxoSmithKline will be able to funnel its extensive marketing dollars into a stable of poised-to-explode brands, niche marketers can take those brands being sold and breathe fresh marketing life into them and retailers now benefit most of all because a greater portfolio of brands are being marketed with gusto.

April 14, 2011

GlaxoSmithKline on Thursday identified the remaining noncore over-the-counter brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands and emerging markets.

LONDON — GlaxoSmithKline on Thursday identified the remaining noncore over-the-counter brands that it intends to divest as the company focuses its Consumer Healthcare business around a portfolio of fast-growing priority brands and emerging markets.

GSK said it planned to contact companies interested in acquiring the brands over the next few weeks and expected to complete all divestitures by late 2011.

March 30, 2011

Dr. Reddy’s Labs will assume ownership of a penicillin manufacturing site in Bristol, Tenn., from GlaxoSmithKline.

HYDERABAD, India — Dr. Reddy’s Labs will assume ownership of a penicillin manufacturing site in Bristol, Tenn., from GlaxoSmithKline.

The generic drug maker said it completed the acquisition of the facility and related product portfolio, including Augmentin and Amoxil brands. GSK will retain the existing rights for the aforementioned brands outside the United States.

Further financial terms and conditions of the transaction are not being disclosed.

January 18, 2011

Colin Mackenzie has been appointed the new president of GlaxoSmithKline Consumer Healthcare North America. Mackenzie succeeds Roger Scarlett-Smith, who is relocating to London to become president of GSK Consumer Healthcare Europe.

PITTSBURGH — Colin Mackenzie has been appointed the new president of GlaxoSmithKline Consumer Healthcare North America. Mackenzie succeeds Roger Scarlett-Smith, who is relocating to London to become president of GSK Consumer Healthcare Europe.

Mackenzie has been directing the U.S. oral care business since 2007. Under the leadership of MacKenzie, the business accelerated its net sales growth rate, acquired the leading dry mouth product, Biotene, in 2008, and claimed the No. 1 toothpaste SKU in the United States (Sensodyne Extra Whitening).

January 5, 2011

WASHINGTON — The Consumer Healthcare Products Association recently named GlaxoSmithKline veteran Janet Carter-Smith chair of the CHPA Retailer Liaison Steering Committee effective Jan. 1. Carter-Smith is the third chair of this committee, succeeding David Howenstine, VP customer and industry development at Pfizer Consumer Healthcare, whose term ended at the end of the year.

December 14, 2010

GlaxoSmithKline on Monday announced its acquisition from Darwin Private Equity of Maxinutrition, a U.K. company that manufactures protein-enhanced functional nutrition products.

LONDON — GlaxoSmithKline on Monday announced its acquisition from Darwin Private Equity of Maxinutrition, a U.K. company that manufactures protein-enhanced functional nutrition products.

“This deal will give GSK a strong presence in the fast-developing protein-based sports nutrition market, appealing across a broad spectrum of consumers, from elite athletes to sports participants and those seeking additional nutritional supplementation,” stated John Clarke, GSK Consumer Healthcare president.

October 26, 2010

British drug maker GlaxoSmithKline will pay nearly $1 billion to the U.S. government to settle...

LONDON British drug maker GlaxoSmithKline will pay nearly $1 billion to the U.S. government to settle allegations that it sold contaminated and ineffective products.

 

The company will plead guilty to criminal charges relating to drugs made at a manufacturing plant in Cidra, Puerto Rico, which it closed in 2009, and pay $750 million. In a whistleblower suit filed by a former employee, it was alleged that the company knowingly sold defective supplies of various drugs, including the baby ointment Bactroban (mupirocin) and the antidepressant Paxil (paroxetine).

September 6, 2010

GlaxoSmithKline Consumer Healthcare on Tuesday named Stacy Wallace to the newly created role of VP...

PITTSBURGH GlaxoSmithKline Consumer Healthcare on Tuesday named Stacy Wallace to the newly created role of VP customer marketing and 360° Insights.

Under Wallace’s direction, the customer marketing and 360° Insights team will continue the development and execution of category visions and strategies in the area of health and wellness and in the creation of insight-led innovative and fully evaluated shopper marketing programs, the company stated.

July 21, 2010

British drug maker GlaxoSmithKline is the latest company to join health policy research organization the...

March 25, 2010

GlaxoSmithKline earlier this week named Emma Walmsley to the post of president, consumer healthcare Europe...